HUE057710T2 - Káliumcsatorna modulátorok - Google Patents

Káliumcsatorna modulátorok

Info

Publication number
HUE057710T2
HUE057710T2 HUE18704122A HUE18704122A HUE057710T2 HU E057710 T2 HUE057710 T2 HU E057710T2 HU E18704122 A HUE18704122 A HU E18704122A HU E18704122 A HUE18704122 A HU E18704122A HU E057710 T2 HUE057710 T2 HU E057710T2
Authority
HU
Hungary
Prior art keywords
potassium channel
channel modulators
modulators
potassium
channel
Prior art date
Application number
HUE18704122A
Other languages
English (en)
Hungarian (hu)
Inventor
Dipak Amrutkar
Kelly Foster
Thomas Jacobsen
Martin JEFSON
Gregg Keaney
Janus Larsen
Karin Nielsen
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Publication of HUE057710T2 publication Critical patent/HUE057710T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
HUE18704122A 2017-01-23 2018-01-23 Káliumcsatorna modulátorok HUE057710T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762449270P 2017-01-23 2017-01-23

Publications (1)

Publication Number Publication Date
HUE057710T2 true HUE057710T2 (hu) 2022-05-28

Family

ID=61188924

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18704122A HUE057710T2 (hu) 2017-01-23 2018-01-23 Káliumcsatorna modulátorok

Country Status (30)

Country Link
US (4) US9975886B1 (enExample)
EP (1) EP3571193B1 (enExample)
JP (1) JP6997197B2 (enExample)
KR (1) KR102664772B1 (enExample)
CN (1) CN110198935B (enExample)
AR (1) AR110770A1 (enExample)
BR (1) BR112019014814B1 (enExample)
CL (1) CL2019002031A1 (enExample)
CO (1) CO2019009060A2 (enExample)
CU (1) CU24560B1 (enExample)
CY (1) CY1125463T1 (enExample)
DK (1) DK3571193T3 (enExample)
EA (1) EA036668B1 (enExample)
ES (1) ES2906078T3 (enExample)
HR (1) HRP20220079T1 (enExample)
HU (1) HUE057710T2 (enExample)
IL (1) IL267954B (enExample)
LT (1) LT3571193T (enExample)
MX (1) MX376080B (enExample)
MY (1) MY195123A (enExample)
PH (1) PH12019501678A1 (enExample)
PL (1) PL3571193T3 (enExample)
PT (1) PT3571193T (enExample)
RS (1) RS62899B1 (enExample)
SG (1) SG11201905893WA (enExample)
SI (1) SI3571193T1 (enExample)
TW (1) TWI751271B (enExample)
UA (1) UA123810C2 (enExample)
WO (1) WO2018136917A1 (enExample)
ZA (1) ZA201904458B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10774064B2 (en) * 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
JP6997197B2 (ja) * 2017-01-23 2022-01-17 カデント セラピューティクス，インコーポレーテッド カリウムチャネルモジュレーター
MX2021004647A (es) * 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
CN118985622B (zh) * 2024-07-05 2025-12-02 云南大学 一种吡唑类化合物在防治植物根结线虫中的应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6059883B2 (ja) 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
GB2183243B (en) 1985-10-09 1990-01-24 Nippon Oil Co Ltd Process for preparing oil-soluble nitrogen-containing compounds
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
LU87304A1 (fr) 1988-07-29 1990-02-07 Oreal Nouveaux derives d'ureylene triamino-2,4,6 pyrimidine oxyde-3,leur preparation et leur utilisation en cosmetique et dermopharmacie
JPH02282251A (ja) 1989-04-24 1990-11-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE4034762A1 (de) 1990-11-02 1992-05-07 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
DK72693D0 (da) 1993-06-18 1993-06-18 Lundbeck & Co As H Compounds
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
WO1998006709A1 (en) 1996-08-14 1998-02-19 Takeda Chemical Industries, Ltd. Cyclic urea compounds, their production and use as herbicides
DE19642863A1 (de) 1996-10-17 1998-04-23 Bayer Ag Amide
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
JPH11282132A (ja) 1998-03-27 1999-10-15 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP2000072695A (ja) 1998-08-24 2000-03-07 Sumitomo Pharmaceut Co Ltd 環状化合物
JP2000075449A (ja) 1998-08-31 2000-03-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像方法
JP2003508509A (ja) 1999-09-04 2003-03-04 アストラゼネカ アクチボラグ ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド
WO2001032170A1 (en) 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
MXPA03000032A (es) 2000-06-29 2003-08-19 Neurosearch As Uso de derivados de oxindol 3-sustituidos como moduladores de los canales de potasio kcnq.
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
CN1592745A (zh) 2001-01-16 2005-03-09 阿斯特拉曾尼卡有限公司 治疗用苯并－γ－吡喃酮化合物
MXPA03006261A (es) 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos terapeuticos de cromano.
BR0206512A (pt) 2001-01-16 2004-01-06 Astrazeneca Ab Composto, método de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de um composto, e, processo para preparar um composto.
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
NZ529043A (en) * 2001-04-16 2006-11-30 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
CN1671639A (zh) 2002-08-23 2005-09-21 康涅狄格大学 新型联苯大麻素和类似联苯的大麻素
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7589092B2 (en) 2003-06-20 2009-09-15 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
WO2005035507A2 (en) 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
MXPA06004191A (es) 2003-10-17 2007-01-19 Incyte Corp Hidroxamatos ciclicos sustituidos en la forma inhibidores de metaloproteinasas de matriz.
JP2007512275A (ja) 2003-11-24 2007-05-17 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾリルおよびイミダゾリルピリミジン
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
AU2005227997A1 (en) 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2005112938A2 (en) 2004-04-13 2005-12-01 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
CA2581454A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
GB0422556D0 (en) 2004-10-11 2004-11-10 Syngenta Participations Ag Novel insecticides
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006077364A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
CA2594773A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
AU2005325497A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
EP1841736A1 (en) 2005-01-19 2007-10-10 Biolipox AB Indoles useful in the treatment of inflammation
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
JP4966958B2 (ja) 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤及び医療における使用
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
EP1863796A1 (en) 2005-03-22 2007-12-12 NeuroSearch A/S Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use
US20060156481A1 (en) 2005-03-22 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
EP1890703B1 (en) 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
CA2617170A1 (en) 2005-07-30 2007-02-08 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
DE102005043165A1 (de) 2005-09-12 2007-03-22 Merck Patent Gmbh Metallkomplexe
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
FR2892859B1 (fr) 2005-10-27 2008-06-06 Commissariat Energie Atomique Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications
EP1962892A4 (en) 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
TW200730478A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(6-membered aromatic ring)-amido anti-viral compounds
TW200730476A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(5-membered aromatic ring)-amido anti-viral compounds
WO2007071632A2 (en) 2005-12-20 2007-06-28 Neurosearch A/S 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
EP1999270A4 (en) 2006-03-13 2010-04-28 Perkinelmer Las Inc SUBSTRATES AND INTERNAL STANDARDS FOR MASS SPECTROSCOPY DETECTION
EP2012769A1 (en) 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
CA2659391A1 (en) 2006-08-03 2008-02-07 Prosensa Technologies B.V. Antibiotic composition
EP2066655A2 (en) 2006-09-07 2009-06-10 Neurosearch A/S Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
MX2009003142A (es) 2006-10-03 2009-04-06 Neurosearch As Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
EP2099778A2 (en) 2006-11-21 2009-09-16 Smithkline Beecham Corporation Amido anti-viral compounds
JP2010511727A (ja) 2006-12-04 2010-04-15 ニューロクライン バイオサイエンシーズ，インコーポレイテッド アデノシン受容体アンタゴニストとしての置換ピリミジン
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
CA2679185A1 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
JP5703432B2 (ja) 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142545A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP5111039B2 (ja) 2007-09-27 2012-12-26 富士フイルム株式会社 重合性化合物、重合開始剤、および染料を含有する光硬化性組成物
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
US8563552B2 (en) 2008-02-08 2013-10-22 Shiseido Company Ltd. Whitening agent and skin external preparation
CA2717110A1 (en) 2008-02-28 2009-09-03 Saint Mary's University Compounds, complexes and uses thereof
EP2276750A2 (en) 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
JP5277256B2 (ja) 2008-04-09 2013-08-28 田辺三菱製薬株式会社 ｍａｘｉ−Ｋチャネル開口薬としてのピリミジン、ピリジン及びトリアジン誘導体
WO2009152902A2 (en) 2008-05-28 2009-12-23 Merck Patent Gmbh, Ionic liquids
AU2009259026B2 (en) 2008-06-11 2012-10-04 Astrazeneca Ab Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2331527A1 (en) 2008-09-02 2011-06-15 NeuroSearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
CN101684098A (zh) 2008-09-24 2010-03-31 中国科学院上海药物研究所 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
AR074870A1 (es) 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
SG177558A1 (en) 2009-07-08 2012-02-28 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AU2010319298B2 (en) 2009-11-13 2015-11-05 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
AT509266B1 (de) 2009-12-28 2014-07-15 Univ Wien Tech Substituierte pyridine und pyrimidine
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012022487A1 (de) 2010-08-20 2012-02-23 Grünenthal GmbH Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors
HUE024870T2 (en) * 2010-08-27 2016-02-29 Gruenenthal Gmbh Substituted 2-oxo and 2-thioxo-dihydroquinoline-3-carboxamides as modulators of KCNQ2 / 3
TW201218480A (en) 2010-09-30 2012-05-01 Basf Se Additive for electrolytes
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9290591B2 (en) 2011-02-08 2016-03-22 President And Fellows Of Harvard College Iron complexes and methods for polymerization
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102731492B (zh) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
BR112013030741A2 (pt) 2011-05-31 2016-12-06 Merck Patent Gmbh compostos contendo ânions de hidreto- triciano-borato
WO2012167171A2 (en) 2011-06-03 2012-12-06 Massachusetts Institute Of Technology Z-selective ring-closing metathesis reactions
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
JP2014525452A (ja) 2011-08-29 2014-09-29 ピーティーシー セラピューティクス， インコーポレイテッド 抗菌化合物および使用方法
JP5741850B2 (ja) 2011-09-13 2015-07-01 コニカミノルタ株式会社 光学フィルム、それを含む偏光板および液晶表示装置
JP5857713B2 (ja) 2011-12-15 2016-02-10 コニカミノルタ株式会社 光学フィルム、偏光板、及び液晶表示装置
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
US20150197503A1 (en) 2012-07-27 2015-07-16 Bial-Portela & Cª, S.A. Process for the synthesis of substituted urea compounds
WO2014031681A1 (en) 2012-08-20 2014-02-27 The University Of Chicago Inhibiting gram positive bacteria
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
BR112015006029B1 (pt) 2012-09-18 2022-01-25 Heptares Therapeutics Limited Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
ES2469290B2 (es) 2012-12-17 2015-01-26 Ocupharm Diagnostics S.L. Mejora en la aplicación tópica de fármacos oculares mediante la administración de nucleótidos
US9279094B2 (en) 2012-12-21 2016-03-08 Afton Chemical Corporation Friction modifiers for use in lubricating oil compositions
US9499762B2 (en) 2012-12-21 2016-11-22 Afton Chemical Corporation Additive compositions with a friction modifier and a detergent
EP2941423B1 (en) 2013-01-07 2021-06-09 University of Southern California Deoxyuridine triphosphatase inhibitors
WO2014108487A1 (en) 2013-01-10 2014-07-17 Universite D'aix-Marseille P-stereogenic chiral precursor of chiral ligands and use thereof
WO2014134141A1 (en) 2013-02-26 2014-09-04 President And Fellows Of Harvard College Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer
WO2014159690A1 (en) 2013-03-12 2014-10-02 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2014165827A1 (en) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
EP3017487B1 (de) 2013-07-02 2021-01-13 Merck Patent GmbH Organische elektrolumineszenzvorrichtung
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP2016529241A (ja) 2013-07-25 2016-09-23 フォンダッツィオーネ・テレソン Ｆａｐｐ２阻害剤及びそれらの使用
US9701635B2 (en) 2013-07-26 2017-07-11 The Regents Of The University Of California C-H fluorination of heterocycles with silver (II) fluoride
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
TR201911140T4 (tr) 2013-10-21 2019-08-21 Merck Patent Gmbh Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
WO2015069752A1 (en) 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
CN103626741A (zh) 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
KR102339016B1 (ko) 2013-11-29 2021-12-14 프로이오닉 게엠베하 마이크로파 조사에 의한 접착제 경화 방법
US20160304466A1 (en) 2013-12-04 2016-10-20 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
EP3489232A3 (en) 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
GB201502412D0 (en) 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
US20170299609A1 (en) 2016-04-18 2017-10-19 Wright State University Treatment of amyotrophic lateral sclerosis with sk channel activators
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
JP6997197B2 (ja) * 2017-01-23 2022-01-17 カデント セラピューティクス，インコーポレーテッド カリウムチャネルモジュレーター
WO2018136918A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels

Also Published As

Publication number Publication date
TW201838985A (zh) 2018-11-01
HRP20220079T1 (hr) 2022-04-15
CN110198935B (zh) 2022-05-31
MX376080B (es) 2025-03-07
CU20190066A7 (es) 2020-03-04
CL2019002031A1 (es) 2019-10-04
CO2019009060A2 (es) 2019-08-30
TWI751271B (zh) 2022-01-01
US9975886B1 (en) 2018-05-22
CN110198935A (zh) 2019-09-03
US20190352293A1 (en) 2019-11-21
PT3571193T (pt) 2022-03-25
PH12019501678A1 (en) 2020-06-01
LT3571193T (lt) 2022-02-10
BR112019014814A2 (pt) 2020-02-27
MY195123A (en) 2023-01-11
SG11201905893WA (en) 2019-08-27
ZA201904458B (en) 2023-04-26
DK3571193T3 (da) 2022-01-17
CU24560B1 (es) 2021-12-08
US20180215746A1 (en) 2018-08-02
IL267954A (en) 2019-09-26
SI3571193T1 (sl) 2022-04-29
IL267954B (en) 2022-02-01
CY1125463T1 (el) 2024-02-16
EP3571193A1 (en) 2019-11-27
US20210380571A1 (en) 2021-12-09
AR110770A1 (es) 2019-05-02
JP6997197B2 (ja) 2022-01-17
EA201991488A1 (ru) 2019-12-30
PL3571193T3 (pl) 2022-04-25
US10351553B2 (en) 2019-07-16
MX2019008682A (es) 2019-09-18
KR20190110572A (ko) 2019-09-30
JP2020504165A (ja) 2020-02-06
BR112019014814B1 (pt) 2024-03-12
UA123810C2 (uk) 2021-06-02
US10717728B2 (en) 2020-07-21
EP3571193B1 (en) 2021-12-01
RS62899B1 (sr) 2022-03-31
WO2018136917A1 (en) 2018-07-26
EA036668B1 (ru) 2020-12-07
ES2906078T3 (es) 2022-04-13
KR102664772B1 (ko) 2024-05-10

Similar Documents

Publication Publication Date Title
MA50014A (fr) Modulateurs de k-ras
DK3743406T3 (da) Tmem16a modulatorer
EP3183346C0 (en) CHANNEL MODULATORS
MA53943A (fr) Modulateurs de ror-gamma
MA55328A (fr) Modulateurs de ror-gamma
EP3684368A4 (en) SELECTIVE P2X3 MODULATORS
CL2018000524S1 (es) Golilla
DE202018003363U8 (de) Handgelenkssphygmomanometer
DK3710726T3 (da) Transmission
EP3428388A4 (en) TUNNEL DRILL
HUE062866T2 (hu) TREX-1 modulátorok
DK3351526T3 (da) Diisopentylterephthalat
DK3488158T3 (da) Kanalpanel
EP3532062A4 (en) ROR GAMMA MODULATORS
EP3728590C0 (en) NEW THIOPHOSPHORAMIDITES
EP3704466A4 (en) ANALYTE DETECTION PROCESS
IL267954B (en) potassium channel modulators
EP3698005A4 (en) POST CLEARERS
DK3453806T3 (da) Tætningselement
FR3050757B1 (fr) Tunnelier
EP3854876A4 (en) MODIFIED CHANNEL RHODOPSIN
EP3521070A4 (en) ÉMETTTEUR
DK3391733T3 (da) Ballepresse
EP3501859A4 (en) Transmitter
DK3176515T3 (da) Kanalsamling